Department of Cardiac Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
Biosci Rep. 2022 May 27;42(5). doi: 10.1042/BSR20211653.
The relationship between microRNA-21 (miRNA-21) and pathogenesis of lung cancer is a considerable focus of research interest. However, to our knowledge, no in-depth meta-analyses based on existing evidence to ascertain the value of miRNA-21 in diagnosis and clinical prognosis of lung cancer have been documented.
We comprehensively searched all the literature pertaining to 'miRNA-21' and 'lung cancer' from four databases from the period of inception of each database until May 2020. Using specific inclusion and exclusion criteria, the literature for inclusion was identified and the necessary data extracted.
In total, 46 articles were included in the meta-analysis, among which 31 focused on diagnostic value and 15 on prognostic value. Combined sensitivity (SEN) of miRNA-21 in diagnosis of lung cancer was 0.77 (95% confidence interval (CI): 0.72-0.81), specificity (SPE) was 0.86 (95% CI: 0.80-0.90), diagnostic odds ratio (DOR) was (95% CI: 12-33), and area under the SROC curve (AUC) was 0.87 (95% CI: 0.84-0.90). No significant correlations were observed between abnormal expression of miRNA-21 and gender, smoking habits, pathological type and clinical stage of lung cancer (P>0.05). In terms of overall survival (OS), univariate analysis (hazards ratio (HR) = 1.49, 95% CI: 1.22-1.82) revealed high expression of miRNA-21 as an influencing factor for lung cancer. MiRNA-21 was confirmed as an independent risk factor for poor prognosis in multivariate analysis (HR = 1.65, 95% CI: 1.24-2.19).
MiRNA-21 has potential clinical value in the diagnosis and prognosis of lung cancer and may serve as an effective diagnostic marker and therapeutic target in the future.
miRNA-21（miRNA-21）与肺癌发病机制的关系是研究的重点。然而，据我们所知，尚无基于现有证据深入分析 miRNA-21 在肺癌诊断和临床预后中的价值的研究。
我们从四个数据库全面检索了从数据库建立到 2020 年 5 月与 miRNA-21 和肺癌相关的所有文献。使用特定的纳入和排除标准，确定了纳入文献并提取了必要的数据。
共有 46 篇文章纳入荟萃分析，其中 31 篇聚焦于诊断价值，15 篇聚焦于预后价值。miRNA-21 诊断肺癌的联合灵敏度（SEN）为 0.77（95%置信区间（CI）：0.72-0.81），特异度（SPE）为 0.86（95% CI：0.80-0.90），诊断比值比（DOR）为（95% CI：12-33），受试者工作特征曲线下面积（AUC）为 0.87（95% CI：0.84-0.90）。miRNA-21 异常表达与肺癌患者的性别、吸烟习惯、病理类型和临床分期无显著相关性（P＞0.05）。在总生存（OS）方面，单因素分析（危险比（HR）=1.49，95% CI：1.22-1.82）显示 miRNA-21 高表达是肺癌的影响因素。多因素分析证实 miRNA-21 是预后不良的独立危险因素（HR=1.65，95% CI：1.24-2.19）。
miRNA-21 在肺癌的诊断和预后中有潜在的临床价值，未来可能成为一种有效的诊断标志物和治疗靶点。
